Abstract
Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Recent Patents on Biotechnology
Title: Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Volume: 3 Issue: 2
Author(s): Francesco Pampaloni, Ernst H. K. Stelzer and Andrea Masotti
Affiliation:
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Abstract: Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Export Options
About this article
Cite this article as:
Pampaloni Francesco, Stelzer H. K. Ernst and Masotti Andrea, Three-Dimensional Tissue Models for Drug Discovery and Toxicology, Recent Patents on Biotechnology 2009; 3 (2) . https://dx.doi.org/10.2174/187220809788700201
DOI https://dx.doi.org/10.2174/187220809788700201 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Retinoids in Clinical Use
Medicinal Chemistry Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design The Cell Wall-Associated Proteins in the Dimorphic Pathogenic Species of Paracoccidioides
Current Protein & Peptide Science Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Cervical Cancer During Pregnancy – An Approach to Diagnosis and Management
Current Women`s Health Reviews Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets From the Sea to Anticancer Therapy
Current Medicinal Chemistry Cytotoxic and Antitumor Potentialities of Aporphinoid Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Machine Learning in Healthcare
Current Genomics TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets A Roadmap of Cancer: From the Historical Evidence to Recent Salivary Metabolites-based Nanobiosensor Diagnostic Devices
Current Metabolomics and Systems Biology (Discontinued) Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets